




2018, Vol. 32(1) 66 –74
© The Author(s) 2017





stimulation improves exercise 
tolerance in patients with advanced 
heart failure on continuous 
intravenous inotropic support  
use—randomized controlled trial
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Abstract
Objective: To evaluate the impact of a short-term neuromuscular electrical stimulation program 
on exercise tolerance in hospitalized patients with advanced heart failure who have suffered an acute 
decompensation and are under continuous intravenous inotropic support.
Design: A randomized controlled study.
Subjects: Initially, 195 patients hospitalized for decompensated heart failure were recruited, but 70 were 
randomized.
Intervention: Patients were randomized into two groups: control group subject to the usual care 
(n = 35); neuromuscular electrical stimulation group (n = 35) received daily training sessions to both lower 
extremities for around two weeks.
Main measures: The baseline 6-minute walk test to determine functional capacity was performed 
24 hours after hospital admission, and intravenous inotropic support dose was daily checked in all patients. 
The outcomes were measured in two weeks or at the discharge if the patients were sent back home 
earlier than two weeks.
Results: After losses of follow-up, a total of 49 patients were included and considered for final analysis 
(control group, n = 25 and neuromuscular electrical stimulation group, n = 24). The neuromuscular electrical 
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stimulation group presented with a higher 6-minute walk test distance compared to the control group after 
the study protocol (293 ± 34.78 m vs. 265.8 ± 48.53 m, P < 0.001, respectively). Neuromuscular electrical 
stimulation group also demonstrated a significantly higher dose reduction of dobutamine compared 
to control group after the study protocol (2.72 ± 1.72 µg/kg/min vs. 3.86 ± 1.61 µg/kg/min, P = 0.001, 
respectively).
Conclusion: A short-term inpatient neuromuscular electrical stimulation rehabilitation protocol 
improved exercise tolerance and reduced intravenous inotropic support necessity in patients with 
advanced heart failure suffering a decompensation episode.
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Introduction
Several studies have demonstrated that neuromus-
cular electrical stimulation therapy significantly 
improves exercise tolerance and quality of life in 
patients with advanced heart failure who cannot 
engage in conventional exercise training.1–3 To this 
point, most of these studies were performed in 
patients with heart failure in the outpatient setting, 
for over several weeks to months.4 Few data are 
available that assess the effects of neuromuscular 
electrical stimulation as a short-term inpatient 
intervention for patients with advanced heart fail-
ure admitted for acute decompensation. In addi-
tion, there are limited studies assessing the 
functional capacity of patients with advanced heart 
failure receiving continuous inotropic infusions.
Therefore, the aim of this study was to evaluate 
the impact of a short-term neuromuscular electrical 
stimulation program on exercise tolerance in hos-
pitalized patients with advanced heart failure who 
have suffered an acute decompensation and are 
under continuous intravenous inotropic support.
Methods
This randomized controlled study was conducted 
at the São Paulo Hospital—Cardiology Unit of the 
Federal University of Sao Paulo, Brazil, between 
January 2010 to December 2014 and was previ-
ously approved by Institutional Ethical Research 
Committee and registered at ClinicalTrials.gov 
(NCT02668419). Prior to study inclusion, all 
patients were informed about the study and a 
signed consent form was obtained from each 
subject.
Hospitalized patients with advanced heart fail-
ure—stage D (left ventricular ejection fraction 
<30%) determined by echocardiography performed 
on the day of hospital admission, at rest, through 
Simpson’s method,5 New York Heart Association 
class III–IV, diagnosis and management of heart 
failure,6 standard medical therapy7 and continuous 
inotropic infusions were included. Exclusion criteria 
were unstable angina pectoris, acute coronary syn-
dromes in the last six months, atrial and ventricular 
arrhythmias leading to hemodynamic compromise, 
diabetes mellitus, peripheral vascular disease and 
neurological or orthopedic conditions that would 
limit performance during the functional assessment. 
Patients with chronic obstructive pulmonary disease 
confirmed by pulmonary function testing according 
to American Thoracic Society standards were also 
excluded.8 Quality of life was performed on admis-
sion using the Minnesota Living with Heart Failure 
Questionnaire to characterize the sample.9 All 
patients underwent standard medical therapy beta-1 
selective blockers (angiotensin-converting enzyme 
inhibitors, aldosterone antagonists and other diuret-
ics) as needed during hospitalization.
Patients hospitalized for decompensated heart 
failure were prospectively randomized into two 
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groups 24 hours after hospital admission and clini-
cal stabilization; control group: patients underwent 
a usual care; the neuromuscular electrical stimula-
tion group: patients received daily neuromuscular 
electrical stimulation sessions to both lower 
extremities. Randomization was generated by the 
software “random.org” and allocation secrecy was 
kept by numbered, sealed, opaque envelopes. The 
outcome measures were assessed by the same 
health professional who was blinded to the patients’ 
group allocation.
Study protocol
Usual care group—each session consisted of 
breathing exercises and global active exercises of 
the upper and lower limbs in bed. The treatment 
was applied twice a day during the hospitalization 
period. The protocol was interrupted if the patient 
had signs or symptoms suggestive of poor toler-
ance to exercise: (1) cyanosis, pallor, dizziness, 
nausea or pre-syncope; (2) chest pain; (3) brady-
cardia; (4) a drop in systolic blood pressure >15 mm 
Hg in comparison to baseline; (5) an excessive rise 
in systolic blood pressure defined as >200 mm Hg; 
(6) a rise in diastolic blood pressure during exer-
cise >110 mm Hg; (7) fatigue rated ≥6/10 on the 
perceived exertion Borg (PEB) scale; and/or (8) 
electrocardiographic signs of cardiac ischemia or 
ventricular arrhythmias.
Neuromuscular electrical stimulation group—
quadriceps and calf muscles of both legs were 
simultaneously stimulated using self-adhesive sur-
face rectangular electrodes (90 × 50 mm) (FESMED 
IV; CARCI, Sao Paulo, Brazil). The electrodes 
were positioned approximately 5 cm below the 
inguinal fold line and 5 cm above the upper patella 
border in order to promote quadriceps stimulation; 
to stimulate the calf muscles, the electrodes were 
positioned approximately 5 cm under the popliteal 
fossa and 5 cm over the Achilles tendon. During all 
session periods, the patients were maintained in the 
supine Fowler 45° position. Stimulation parameters 
were set up as follows: biphasic current of 40 Hz, 
400-µs pulse duration, mode “on-time” 10 seconds 
and “off-time” 20 seconds and maximal amplitude 
of 60 mA. The stimulation intensity progressively 
increased according to the patient tolerance until a 
muscular contraction was observed. The stimula-
tion program was performed during the patient’s 
in-hospital period, which lasted around two weeks, 
twice a day; the session duration was 60 minutes 
including 5 minutes for warm up and 5 minutes for 
recovery. Heart rate, blood pressure, respiratory 
rate and pulse oximetry were monitored through-
out the sessions, in all patients. Patients were 
instructed to leave bed and rest in a bedside chair at 
least twice a day outside the sessions associated 
with the protocol.
Outcome measures. Functional capacity was evalu-
ated using the 6-minute walk test, in accordance 
with American Thoracic Society criteria.10 For this 
analysis, a baseline 6-minute walk test was per-
formed 24 hours after hospital admission and clini-
cal stabilization.
During the test, all patients were taking intrave-
nous inotropic drugs administered by an infusion 
pump which was carried out by the same blinded 
evaluator who walked at patient’s side. The 6-min-
ute walk test would be discontinued if the patient 
presented with signs or symptoms suggestive of 
exercise intolerance as described above. The pre-
diction equation proposed by Iwama et al.11 was 
used to predict 6-minute walk test distance for all 
patients. For all patients, the inotropic intravenous 
dose was adjusted daily by a single clinician (pre-
scriber) blinded to the group allocation, and wean-
ing from inotropic support was based on the 
improvement in clinical signs.
The follow-up 6-minute walk test and inotropic 
intravenous dose were measured in two weeks or at 
the discharge if the patients were sent back home 
earlier than two weeks.
Statistical analysis
Based on the results of previous studies,12 the sam-
ple size was calculated for detecting at least a 40m 
difference in 6-minute walk test distance with a 
power of 80% and alpha risk of 5% (P < 0.05). For 
this study, the sample size needed to achieve the 
calculated study power was 24 patients per group. 
This assumption suggested a sample of 48 patients, 
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resulting in a sample of 70 patients to cover attri-
tion. Variables were described as mean ± standard 
deviation. The Student’s unpaired t-test and Mann–
Whitney test were used for comparing as appropri-
ate. For intragroup comparison, the Student’s 
paired t-test and Wilcoxon test were used as appro-
priate. The analysis of categorical data was per-
formed by the Pearson chi-square test. The Pearson 
correlation coefficient was used to evaluate asso-
ciations between 6-minute walk test distance and 
the intravenous inotropic support. Statistical analy-
sis was performed by GraphPad Prism 3.0 software 
(GraphPad Software Inc., San Diego, CA, USA). 
For all statistical tests, a P-value < 0.05 defined sta-
tistical significance.
Results
During the study period, 195 patients were assessed 
for eligibility, and from that sample, 70 were rand-
omized and allocated into the two groups; after 
excluding losses of follow-up, 49 patients com-
pleted the study (control group, n = 25 and neuro-
muscular electrical stimulation group, n = 24) as 
shown in Figure 1. A total of 11 patients died dur-
ing the study period (control group, n = 6 and neu-
romuscular electrical stimulation group, n = 5).
The groups were homogeneous and no statisti-
cal difference was found with respect to key base-
line characteristics as shown in Table 1. The 
protocols were well tolerated by patients of both 
groups. No muscle soreness and/or electrode-asso-
ciated skin alterations were observed. The duration 
of the treatment was 12.13 days in the control group 
and 13.15 days in the neuromuscular electrical 
stimulation group (P = 0.33).
Regarding functional capacity, the groups were 
homogeneous on baseline and a significant 
improvement in 6-minute walk test distance was 
seen in both groups post-protocol, compared to the 
baseline values (P < 0.05). However, stimulation 
group exhibited a significantly higher increase 
compared to the control group after protocol appli-
cation (P < 0.001) (Table 2).
Concerning intravenous inotropic support, both 
groups were homogeneous at baseline and attained 
a reduction in the dobutamine dose post-protocol in 
relation to baseline (P < 0.001). When the groups 
were compared after protocol application, the neu-
romuscular electrical stimulation group showed a 
significantly higher dose reduction of dobutamine 
compared to the control group (P = 0.001) (Table 
2). Moreover, there was a significant negative cor-
relation between the 6-minute walk test distance 
and intravenous inotropic support at protocol com-
pletion (r = −0.7; P < 0.001).
Discussion
Our study showed that a short-term inpatient neu-
romuscular electrical stimulation protocol was able 
to improve functional capacity, exercise tolerance 
and reduce the need for intravenous inotropic sup-
port at a faster trajectory in patients with advanced 
heart failure hospitalized for an acute decompensa-
tion. This analysis appears to be a novel addition to 
the literature and further supports the utility of neu-
romuscular electrical stimulation in this chronic 
disease population, particularly in those with an 
advanced disease phenotype.
Conventional methods of exercise rehabilitation 
(i.e. aerobic and resistance) in patients with New 
York Heart Association classes III–IV can be lim-
ited by dyspnea, fatigue or exhaustion due to low 
peripheral oxygen supply.13 Immobilization has 
been shown to be a factor that may partly contrib-
ute to enhance the skeletal muscle weakness in 
patients hospitalized with heart failure.14 The cur-
rent literature suggest that these heart failure 
patients with advanced disease severity (i.e. New 
York Heart Association III–IV) benefit from activi-
ties that produce muscle contractions to reduce loss 
of muscle mass that significantly impacts func-
tional capacity.1,15,16
Studies have emphasized the need of new reha-
bilitation approaches for severely compromised 
heart failure patients who have suffered an acute 
decompensation episode.1,3 In this context, neuro-
muscular electrical stimulation has been used in 
several studies with a positive impact on functional 
capacity and quality of life and is being increas-
ingly recommended as a tool for rehabilitation in 
patients with advanced heart failure and profound 
functional deficits.3,4,13,17,18
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Nevertheless, most of these studies were con-
ducted in patients with heart failure in the outpatient 
setting, often for duration of at least eight weeks.1,4,17 
Therefore, a novel aspect of our study was to test 
the application of neuromuscular electrical stimula-
tion over a short period of time in patients with 
Figure 1. Flowchart of the study.
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advanced heart failure suffering an acute decom-
pensation and requiring continuous dobutamine in 
the inpatient setting.
Previous studies have shown that heart failure 
patients with a phenotype similar to those included 
in the current analysis have a higher risk of 
morbidity (high risk of re-hospitalization) and 
mortality.19,20 In our study, both groups presented 
at baseline with a mean 6-minute walk test distance 
less than 300 m, highlighting the advanced disease 
Table 1. Demographic and clinical characteristics.
Variables Control group (n = 25) Neuromuscular electrical 
stimulation group (n = 24)
P-value
Age (years), mean (SD) 51.52 (11.03) 52.58 (14.71) 0.40
Female/Male, n 3/22 5/19 0.20
BMI (kg/m2), mean (SD) 23.61 (4.08) 22.14 (2.47) 0.08
Etiology, n 15 ischemic 14 ischemic 0.45
02 idiopathic 04 idiopathic  
07 hypertensive 05 hypertensive  
01 valve 01 non-compact 
myocardium
 
ICD/pacemaker, n 13 15 0.22
LVEF, mean (SD) 0.25 (0.03) 0.27 (0.04) 0.09
MLHFQ score, mean (SD) 72.38 (12.11) 77.10 (12.03) 0.10
Pulmonary function
 FVC (L), mean (SD) 2.94 (0.67) 2.84 (0.82) 0.34
 % predicted 75.92 (9.08) 74.84 (10.5)  
 FEV1 (L), mean (SD) 2.55 (0.61) 2.74 (0.74) 0.25
 % predicted 84.41 (12.54) 87.65 (9.58)  
Drug therapy
  Angiotensin converting enzyme inhibitors 
(mg/day), mean (SD)
20.22 (16.74) 22.30 (21.31) 0.35
 Furosemide (mg/day), mean (SD) 30.45 (10.24) 29.20 (10.21) 0.32
 Length of exercise sessions (days), mean (SD) 12.13 (1.21) 13.15 (2.4) 0.33
SD: standard deviation of the mean; BMI: body mass index; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; 
ICD: implanted cardioverter defibrillator; LVEF: left ventricular ejection fraction; MLHFQ: Minnesota Living with Heart Failure 
Questionnaire.
Table 2. Distance in the 6-minute walk test and intravenous inotropic support between groups after study 
protocol.
Variables Control group  
(n = 25)
Neuromuscular electrical 
stimulation group (n = 24)
Baseline Post-protocol Baseline Post-protocol
Distance (m), mean (SD) 237.8 (40.50) 265.8 (48.53)* 238 (47.43) 293 (34.78)*†
% predicted 40.05 (6.37) 42.52 (9.57)  
Dobutamine (µg/kg/min), mean (SD) 8.02 (3.81) 3.86 (1.61)* 8.87 (3.63) 2.72 (1.72)*†
SD: standard deviation of the mean.
*P < 0.05 baseline vs. post-protocol; †P < 0.05 control group vs. neuromuscular electrical stimulation group study post-protocol.
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severity and clinical fragility of these patients. 
Even so, there were no adverse events with the use 
of neuromuscular electrical stimulation, indicating 
the safety of this therapeutic intervention in com-
promised patients, even in patients with implanted 
cardioverter defibrillators, consistent with previous 
studies.17,21
With respect to improvements in functional 
capacity, both groups demonstrated a significant 
increase in 6-minute walk test distance after the 
exercise protocol. However, the patients in the neu-
romuscular electrical stimulation arm demon-
strated an increase of 56 m in relation to baseline 
values, while the usual care group achieved an 
increase of 28 m. These findings support the ability 
of neuromuscular electrical stimulation to signifi-
cantly augment functional recovery during inpa-
tient care in patients with advanced heart failure. 
Previous investigations have stated an increase in 
6-minute walk test of at least 45 m is needed to sup-
port therapeutic efficacy.22 However, previous 
work has not assessed the 6-minute walk test dis-
tance improvement indicative of a meaningful clin-
ical difference in heart failure patients undergoing 
continuous inotropic infusion. Even so, the results 
of this study are consistent with the previously 
defined criteria for a meaningful clinical improve-
ment by 6-minute walk test distance criteria in 
patients receiving neuromuscular electrical stimu-
lation. Our results are consistent with a recent 
study23 where hospitalized patients with heart fail-
ure (New York Heart Association II–III) without 
inotropic support underwent daily neuromuscular 
electrical stimulation sessions for 15 days and also 
presented with a clinically significant increase in 
6-minute walk test distance.
Studies showing that patients who covered a 
longer 6-minute walk test distance have a decreased 
likelihood of death or hospitalization for inotropic 
or mechanical support.19,20,24 In this context, our 
findings suggest that neuromuscular electrical 
stimulation may improve outcome by achieving a 
significantly greater 6-minute walk test distance; 
future research is needed to address this question. 
Despite widespread use, evidences indicate that 
dobutamine is not associated with mortality reduc-
tion and is in fact associated with an increase in 
mortality. It was suggested that more research is 
needed to define the clinical role of dobutamine in 
the treatment of advanced heart failure.25 Our find-
ings indicate that neuromuscular electrical stimula-
tion may accelerate dobutamine weaning which 
has clear benefits.
When the correlation among the functional 
capacity and the intravenous inotropic support in 
all patients was performed after protocol comple-
tion, we found a reduced need of inotropic support 
in patients with a longer 6-minute walk test dis-
tance; neuromuscular electrical stimulation appears 
to significantly improve the distance achieved.
We believe that the mechanism for a positive 
impact on functional status and the reduced need 
for dobutamine observed in the neuromuscular 
electrical stimulation group has a physiologic 
rationale similar to traditional exercise training 
studies in patients with heart failure.2,5 The positive 
impact of neuromuscular electrical stimulation has 
been attributed to several factors such as increased 
aerobic enzyme activity due to an augment of 
peripheral blood flow, enhanced muscle vasculari-
zation and mitochondrial volume and inhibition of 
protein degradation.26 The potential ability of neu-
romuscular electrical stimulation to improve the 
peripheral vasodilator response, with a reduction in 
peripheral vascular resistance and a concomitant 
decrease in cardiac afterload that reduces end-sys-
tolic wall stress and consequently decreases ino-
tropic overload,2,13,27 is a particularly attractive 
physiologic mechanism of improvement for 
patients with advanced heart failure. Besides, stud-
ies indicate that exercise training to be an impor-
tant factor to regulation of cardiac adrenergic beta 
receptors that are deficient in patients with heart 
failure, and this fact appears to contribute to wean-
ing from dobutamine.28
This study has limitations. First, the results are 
limited by a lack of a sham neuromuscular electri-
cal stimulation arm in patients assigned to the con-
trol group. Second, a cut-off that determines the 
prognostic value and clinical impact of an increase 
in the distance covered during inpatient rehabilita-
tion in patients with advanced heart failure under 
continuous use of dobutamine has not yet been 
reported, limiting conclusions that can be drawn 
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from our findings. Third, the patients lost for fol-
low-up, who had complications like convulsion, 
acute pulmonary edema and severe arrhythmias, 
had no final outcome evaluation. Fourth, in this 
study, we looked only at the immediate effects, and 
the long-term benefits still need a further study. 
Thus, additional research is needed in this area.
In conclusion, a short-term inpatient neuromus-
cular electrical stimulation rehabilitation protocol 
improved exercise tolerance and reduced continu-
ous intravenous inotropic support necessity in 
patients with advanced heart failure suffering a 
decompensation episode. As such, if confirmed by 
additional studies, the use of neuromuscular elec-
trical stimulation in this setting may become a 
standard of care.
Clinical Messages
•• Our results suggest that in patients admit-
ted to hospital with decompensated 
advanced heart failure, neuromuscular 
electrical stimulation may improve exer-
cise tolerance and reduce the need for 
inotropic support.
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